<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Carcinoma of the penis: Surgical and medical treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Carcinoma of the penis: Surgical and medical treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Carcinoma of the penis: Surgical and medical treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Curtis A Pettaway, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lance C Pagliaro, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H118143968">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cancers of the penis are rare in the United States, Europe, and other industrialized countries. However, the incidence of penile carcinoma is much higher in parts of South America, Africa, and Asia. (See
         <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">
          "Carcinoma of the penis: Epidemiology, risk factors, and pathology"
         </a>
         .)
        </p>
        <p>
         The treatment of squamous cell carcinoma of the penis is reviewed here. Related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">
          "Carcinoma of the penis: Epidemiology, risk factors, and pathology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14922442">
         <span class="h1">
          TREATMENT OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) eighth edition staging system  (
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         ) is used for staging carcinoma of the penis. (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'TNM staging evaluation'
         </a>
         .)
        </p>
        <p>
         Following initial evaluation, staging and treatment of the primary lesion and the regional lymph nodes are performed separately. Our overall approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary tumor
         </strong>
         – In general, men with a low risk of recurrence are candidates for organ-preserving treatment, whereas men with a high risk of recurrence should be treated by penile amputation  (
         <a class="graphic graphic_algorithm graphicRef114726" href="/z/d/graphic/114726.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Treatment of the primary tumor'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For men with a small distal, noninvasive, or minimally invasive primary tumor, treatment depends on whether the lesion can be adequately controlled with topical therapy, limited excision techniques, or radiation therapy (RT) in an effort to preserve penile form, function, or both  (
         <a class="graphic graphic_figure graphicRef76391 graphicRef66964" href="/z/d/graphic/76391.html" rel="external">
          figure 1A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For men with bulky stage T2 to T4 primary tumors, primary tumor control essentially requires amputation to achieve tumor-free margins and low rates of local recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regional lymph nodes
         </strong>
         – The need for surgical staging and subsequent treatment of the regional lymph nodes is based upon characteristics of the primary tumor (ie, grade, stage, lymphovascular invasion, perineural invasion) as well as the presence or absence of palpable inguinal lymphadenopathy  (
         <a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef114728" href="/z/d/graphic/114728.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef114729" href="/z/d/graphic/114729.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="local">
          'Approach to the regional nodes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Locally advanced disease
         </strong>
         – Men with locally advanced disease (ie, unresectable primary tumor and/or bulky lymphadenopathy) should be treated initially with systemic or multimodal therapy rather than surgery or RT alone. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrent or metastatic disease
         </strong>
         – The approach to men with recurrent or metastatic penile carcinoma depends upon whether disease is localized and potentially curable, whether adjacent structures are involved (ie, major blood vessels, vital organs), or whether distant metastatic disease is present. (See
         <a class="local">
          'Recurrent or metastatic disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1159395689">
         <span class="h1">
          TREATMENT OF THE PRIMARY TUMOR
         </span>
        </p>
        <p class="headingAnchor" id="H6182223">
         <span class="h2">
          Tumors with a low risk of recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary tumors with a low risk of recurrence include Tis involving shaft skin and glans penis, Ta lesions involving the glans only, and T1a and T1b lesions involving the shaft skin and glans alone  (
         <a class="graphic graphic_figure graphicRef76391 graphicRef66964" href="/z/d/graphic/76391.html" rel="external">
          figure 1A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1159395874">
         <span class="h3">
          Limited excision
         </span>
         <span class="headingEndMark">
          —
         </span>
         The objective of a limited excision is to preserve as much of the anatomy of the penis as possible in order to maintain penile length and sexual function while not compromising complete resection of the cancer. Minimally invasive tumors involving the glans (Tis, Ta, T1) and foreskin are most amenable to these techniques. However, small distal T2 glanular lesions can sometimes be resected with negative margins using a glans-sparing technique or with complete glans resection alone, sparing the corporal bodies.
        </p>
        <p>
         The results with a conservative surgical procedure are illustrated by a study from the United Kingdom that analyzed outcomes among 179 patients treated over an eight-year period [
         <a href="#rid1">
          1
         </a>
         ]. Surgical procedures used in this series included circumcision, wide local excision with primary closure or skin graft placement, removal of the glans, or removal of the glans and distal corpora. The mean distance between the microscopic tumor and the resection margin was approximately 5 mm. At a median follow-up of 39 months (range 4 to 107), the local recurrence rate was 9 percent, with a projected five-year freedom from recurrence rate of 86 percent. Predictors of local recurrence were tumor grade and lymphovascular invasion. However, distance to the resection margin was not a significant predictor of recurrence.
        </p>
        <p>
         Excision to negative margins is critical, with a minimum tumor-free margin of 1 mm or greater. One study from the United Kingdom evaluated the issue of distance of tumor from a negative margin and the risk of recurrence. Among a cohort of 332 patients undergoing organ-sparing surgical procedures in whom the surgical margins were negative, the recurrence rate was 6.4 percent. However, among the cohort of patients with less than a 1 mm tumor-free surgical margin, the incidence of recurrence was approximately six times greater than those with a margin distance &gt;1 mm [
         <a href="#rid2">
          2
         </a>
         ]. In another study of 64 penectomy specimens, histologic grade was highly correlated with microscopic tumor extension beyond the grossly negative margin [
         <a href="#rid3">
          3
         </a>
         ]. The maximum tumor extension was 5 mm for grade 1 to 2 tumors and up to 10 mm for grade 3 tumors. A historically recommended surgical margin of 2 cm is no longer mandated.
        </p>
        <p class="headingAnchor" id="H6182384">
         <span class="h3">
          Alternative organ-preserving strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, alternative organ-preserving strategies should be reserved for men with small, low-stage primary (Tis, Ta, T1) penile tumors. Available options include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Topical therapy, laser ablation, and total glans resurfacing (TGS) are primarily used for Tis lesions (ie, penile intraepithelial neoplasia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mohs micrographic surgery (MMS) is sometimes used for Tis to T1 lesions. (See
         <a class="medical medical_review" href="/z/d/html/13708.html" rel="external">
          "Mohs surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Penile radiation therapy (RT; external beam or interstitial brachytherapy) can be used for Tis, T1, and T2 lesions &lt;4 cm.
        </p>
        <p>
        </p>
        <p>
         The choice of treatment approach depends upon the available local expertise and patient preference.
        </p>
        <p class="headingAnchor" id="H12814023">
         <span class="h4">
          Topical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (5 percent cream applied every other day for four to six weeks) and
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         (5 percent cream applied five days a week for four to six weeks) are used topically to treat carcinoma in situ. However, data on long-term outcomes with topical treatment are limited due to the small sample sizes in single-institution studies [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         In one of the largest reports, 44 men received topical therapy for carcinoma in situ, with
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         used as first-line treatment and
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         as second-line therapy [
         <a href="#rid5">
          5
         </a>
         ]. With a mean follow-up of 34 months, 31 men had a response to treatment, and in 25, it was a complete response. With a median follow-up of 34 months (range 12 to 180), 20 men remained in remission.
        </p>
        <p class="headingAnchor" id="H12814046">
         <span class="h4">
          Laser ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laser ablation utilizes a laser energy source to penetrate and ablate the tumor. Commonly used energy sources include carbon dioxide (CO
         <sub>
          2
         </sub>
         ), argon, neodymium-doped yttrium aluminium garnet (Nd:YAG), and potassium titanyl phosphate [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Laser ablation is associated with a high rate of resumption of sexual activity and sexual satisfaction [
         <a href="#rid7">
          7
         </a>
         ], but its use appears most successful among patients with carcinoma in situ. For men considering laser ablation, the penis must be examined after application of 5 percent acetic acid to identify premalignant areas that will require treatment [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Several retrospective series have provided information about long-term outcome after laser therapy [
         <a href="#rid10">
          10-12
         </a>
         ]. As an example, in one series that evaluated 104 patients treated with excision plus laser therapy, there was a higher local recurrence rate compared with that of 100 men managed with partial amputation (38 versus 10 percent) [
         <a href="#rid10">
          10
         </a>
         ]. However, local control was achieved in more than 90 percent of those who experienced a local recurrence.
        </p>
        <p class="headingAnchor" id="H12814061">
         <span class="h4">
          Total glans resurfacing
         </span>
         <span class="headingEndMark">
          —
         </span>
         TGS removes the skin and lamina propria layers of the glans penis down to the corpus spongiosum, followed by placement of a skin graft [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         The evidence to support its use in low-risk penile carcinoma is limited to single-institution case reports and small series [
         <a href="#rid13">
          13-15
         </a>
         ]. As an example, in one report, 25 men with carcinoma in situ were treated with either TGS or partial glans resurfacing [
         <a href="#rid14">
          14
         </a>
         ]. With a mean follow-up of 29 months (range 2 to 120), 24 men had excellent graft take. However, seven men (28 percent) required further surgery, and in five of these cases, it was due to incidental detection of invasive disease. However, the overall local recurrence rate was only 4 percent. In another series, excellent skin graft take was observed in 19 patients. At mean follow-up of 23 months, the recurrence incidence was 5 percent [
         <a href="#rid15">
          15
         </a>
         ]. Additionally, excellent sexual function was noted using International Index of Erectile Function scores [
         <a href="#rid15">
          15
         </a>
         ]. Additional follow-up will be required to determine the long-term efficacy of TGS.
        </p>
        <p class="headingAnchor" id="H12814071">
         <span class="h4">
          Mohs micrographic surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMS involves layer-by-layer excision of the penile lesion. It is performed in multiple sessions and provides improved precision while maximizing organ preservation. MMS is performed by a dermatologic surgeon with specific training but requires careful coordination between the MMS surgeon and the urologist to optimize patient care.
        </p>
        <p>
         The results with MMS are illustrated by a series of 33 patients (15 with invasive lesions) who underwent 41 MMS procedures between 1988 and 2006 at a single institution [
         <a href="#rid16">
          16
         </a>
         ]. Overall, eight patients (24 percent) had a local recurrence, of which seven were managed with repeat MMS. Only one patient ultimately required penectomy, and one patient died of metastatic penile cancer.
        </p>
        <p class="headingAnchor" id="H12814079">
         <span class="h4">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Penile RT can be administered by either external beam or interstitial brachytherapy techniques. However, the rate of tumor control using external beam RT appears to be inferior to interstitial brachytherapy, as noted in a 2009 review [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         The most extensive experience with brachytherapy comes from a subsequent series of 201 patients with invasive squamous cell carcinoma of the glans penis treated at a French center over a period of 45 years [
         <a href="#rid18">
          18
         </a>
         ]. With a median follow-up of 10.7 years, the estimated five-year local control rate was 82 percent, and the five-year overall survival rate was 79 percent. Local relapse was the initial site of recurrence in 37 cases (19 percent), and 24 of the 31 patients (77 percent) who recurred locally and received additional therapy remained in complete remission. At last follow-up, 25 patients had undergone partial surgical resection of the penis, and seven required total penectomy.
        </p>
        <p>
         High doses of RT are generally needed to eradicate penile squamous cell carcinoma. Because of this, complications are common, including urethral mucositis, edema, and secondary infection [
         <a href="#rid19">
          19
         </a>
         ]. Late complications (eg, telangiectasia, dyschromia, superficial necrosis, urethral stricture, fistula formation, meatal stenosis) can also occur [
         <a href="#rid19">
          19-23
         </a>
         ].
        </p>
        <p>
         Prognostic factors for a poor response among patients treated with RT include [
         <a href="#rid17">
          17,24-26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total treatment dose less than 60 Gy or use of daily fractions less than 2 Gy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protracted treatment time greater than 45 days
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T3 or greater tumor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor larger than 4 cm
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High tumor grade
        </p>
        <p>
        </p>
        <p>
         Circumcision is necessary prior to RT to ensure full exposure of the penile cancer, allow resolution of any surface infection, and prevent maceration and preputial edema. For men who undergo RT, careful follow-up is still required given the risk of local recurrence. Such recurrences may be successfully treated with surgery if diagnosed early. (See
         <a class="local">
          'Posttreatment surveillance'
         </a>
         below and
         <a class="local">
          'Localized recurrence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6182816">
         <span class="h2">
          Tumors with a higher risk of recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with bulky T2 to T4 tumors  (
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         ) are considered to have a high risk of recurrence without adequate treatment.
        </p>
        <p>
         Most of these patients will require penile amputation and are not candidates for a limited excision or organ preservation (see
         <a class="local">
          'Penile amputation'
         </a>
         below). There are some exceptions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distal, smaller, T2 tumors can be successfully treated with limited excisions as long as a tumor-free margin can be achieved. (See
         <a class="local">
          'Limited excision'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interstitial brachytherapy may be an option in select patients who refuse surgery. (See
         <a class="local">
          'Radiation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Patients with large, invasive (ie, bulky stage T2 to T4), or destructive tumors (ie, bulky stage Ta, verrucous cancers) should be treated with penile amputation in order to achieve rapid control of the primary tumor and to identify those patients requiring additional staging of the inguinal and regional nodes. (See
         <a class="local">
          'Approach to the regional nodes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1159395886">
         <span class="h3">
          Penile amputation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Penile amputation includes either partial or total removal of the penis, which is determined by the location and extent of the primary tumor [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial amputation
         </strong>
         – A partial amputation involves the removal of the glans penis with or without a portion of the underlying corpora cavernosa. This procedure is usually performed for distal invasive tumors in situations where resection of the tumor may leave the patient with sufficient penile length to enable micturition while standing. In addition, preservation of penile length may be possible for select men with distal tumors amenable to removal of the glans alone [
         <a href="#rid3">
          3,28-30
         </a>
         ]. (See
         <a class="local">
          'Limited excision'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Total amputation
         </strong>
         – A total amputation involves removal of the glans penis and most, if not all, of the underlying corporal bodies. The urethra is brought out on the perineum as a urethrostomy in order to facilitate voiding in a sitting position. Total amputation is indicated if the tumor cannot be controlled while sparing sufficient length for the patient to stand and void. This is often the case for very large tumors extending down the shaft.
        </p>
        <p>
        </p>
        <p>
         Partial penectomy is performed more commonly [
         <a href="#rid27">
          27,31
         </a>
         ]. In a review of seven surgical series, total penectomy accounted for 23 percent of 1176 procedures, with the remainder consisting of partial penectomy [
         <a href="#rid27">
          27
         </a>
         ]. Local recurrence rates following penectomy range from 3 to 33 percent, with most series reporting recurrence rates of ≤10 percent. The most common complication of penectomy is meatal stenosis, which occurs in 4 to 9 percent of cases.
        </p>
        <p>
         Men who undergo amputation should be counselled regarding the option of penile reconstruction [
         <a href="#rid32">
          32
         </a>
         ]. Whether this is an option and the technical aspects of penile reconstruction are highly dependent upon the type of surgery performed and the risk of recurrence following surgery.
        </p>
        <p class="headingAnchor" id="H118145918">
         <span class="h1">
          APPROACH TO THE REGIONAL NODES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Penile cancer progresses in a predictable manner [
         <a href="#rid33">
          33
         </a>
         ]. There is a prolonged locoregional phase characterized by sequential involvement of the inguinal and pelvic nodes. Distant metastases generally develop following nodal metastases. The presence and extent of inguinal node metastases are the most important prognostic factors for long-term survival [
         <a href="#rid31">
          31,34,35
         </a>
         ].
        </p>
        <p>
         There are multiple techniques used to evaluate and document the histology of the inguinal nodes, including ultrasound with fine needle aspiration (FNA), dynamic sentinel node biopsy (DSNB), and superficial inguinal lymph node dissection (LND). Patients with disease identified in a pathologically positive sentinel node, superficial dissection, or a positive FNA require further surgical resection of the regional nodes. Staging approaches using FNA, DSNB, and superficial inguinal LND (SILND) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Staging techniques'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H542298563">
         <span class="h2">
          Clinically negative examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Men with a clinically negative inguinal node examination may need inguinal node staging based upon the estimated risk of tumor metastasis  (
         <a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">
          algorithm 2
         </a>
         ) or imaging.
        </p>
        <p class="headingAnchor" id="H1035703156">
         <span class="h3">
          Prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several factors help predict the risk of microscopic inguinal lymph node metastases and are incorporated into the eighth edition of the tumor, node, metastasis (TNM) staging system [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary tumor pathologic stage
         </strong>
         – Penile carcinoma in situ (Tis), verrucous carcinoma, and low-grade noninvasive carcinomas (Ta) are rarely (if ever) metastatic [
         <a href="#rid33">
          33,36
         </a>
         ]. However, tumors that involve the subepithelial connective tissue alone are heterogeneous for metastatic potential. As an example, the reported incidence of inguinal metastases for stage T1a tumors are 10 to 18 percent [
         <a href="#rid37">
          37
         </a>
         ]. However, among those with stage T1b tumors, the reported inguinal metastatic rates range between 33 and 50 percent, which is similar to the rates seen among men with pT2-4 primary tumors (33 to 52 percent) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor grade
         </strong>
         – In addition to tumor stage, metastatic potential is associated with high tumor grade. The reported risk of nodal invasion ranges from 0 to 48 percent for grade 1, 32 to 79 percent for grade 2, and 47 to 100 percent for grade 3 tumors [
         <a href="#rid38">
          38
         </a>
         ]. In one study, men with moderate- and high-grade tumors had a significantly worse survival rate at 10 years compared with those with well-differentiated carcinoma [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The reproducibility of the current grading system for penile cancer has come into question in a study from Germany [
         <a href="#rid39">
          39
         </a>
         ]. In addition, the World Health Organization (WHO) and the International Society of Urologic Pathology (ISUP) have recommended that any proportion of anaplastic cells now be designated as grade 3 as part of the eighth edition TNM system [
         <a href="#rid36">
          36
         </a>
         ]. This may facilitate more-uniform identification of tumors with aggressive biology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presence or absence of lymphovascular or perineural invasion
         </strong>
         – The presence of lymphovascular invasion within the primary tumor is the strongest prognostic factor for lymph node metastases, with an associated risk ranging from 60 to 80 percent [
         <a href="#rid38">
          38
         </a>
         ]. In another study, perineural invasion was found to significantly increase the risk of metastatic disease (69 percent of patients) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2883964608">
         <span class="h3">
          Risk stratification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon these prognostic factors, penile cancer guideline panels have stratified men into low- and high-risk groups, which determine the approach to the regional nodes [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low risk
         </strong>
         – Men with Tis, Ta, and T1a tumors exhibiting no lymphovascular or perineural invasion and that are not grade 3 (using the eighth edition TNM definition  (
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid36">
          36
         </a>
         ]) and who have no palpable inguinal adenopathy are considered to be at low risk for nodal metastases. The approach to regional nodes in these low-risk patients is discussed below. (See
         <a class="local">
          'Treatment of low-risk disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High risk
         </strong>
         – In contrast, men with grade 3 tumors, lymphovascular or perineural invasion (≥T1b), and T2 or higher stage are all considered to be at high risk for nodal involvement. The approach to regional nodes in these high-risk patients is discussed below. (See
         <a class="local">
          'Treatment of high-risk disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H525452">
         <span class="h3">
          Inguinal staging procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         DSNB, SILND and modified inguinal LND have been utilized to determine the presence of microscopic metastases among patients with invasive penile tumors and no palpable inguinal adenopathy. All are acceptable alternatives according to treatment guidelines [
         <a href="#rid42">
          42-48
         </a>
         ]. We prefer either DSNB or complete superficial dissection over modified dissections, as the latter had an inguinal recurrence risk of 21 percent in one series [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Regional lymph node assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4116616261">
         <span class="h4">
          Dynamic sentinel node biopsy (DSNB)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to dynamic sentinel lymph node biopsy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Dynamic sentinel node biopsy (DSNB)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H987361312">
         <span class="h4">
          Superficial inguinal lymph node dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing an SILND, intraoperative frozen sections are performed and, if a positive node is found, a therapeutic inguinal LND should be performed, which involves removal of those nodes deep to the fascia lata contained within the femoral triangle. A pelvic lymphadenectomy should also be performed in the case of advanced inguinal disease  (
         <a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimally invasive surgical techniques
         </strong>
         – Both laparoscopic (LAP) and robotic-assisted inguinal lymphadenectomy (RAIL) have an emerging role as minimally invasive staging procedures to remove the inguinal nodes, especially among patients with clinically negative nodes (cN0) and those with minimal palpable adenopathy. Data suggest that such procedures are safe and can adequately remove the regional nodes, as judged by inguinal lymph node counts [
         <a href="#rid49">
          49-54
         </a>
         ]. As an example, one observational series compared RAIL to standard open inguinal lymphadenectomy among 151 patients with cN0 to minimal palpable adenopathy [
         <a href="#rid52">
          52
         </a>
         ]. Compared with the standard surgery group, patients treated with RAIL experienced slightly longer operating room time but a significantly lower incidence of major complications. Both groups had similar lymph node yields and no inguinal recurrences at approximately 40 months of follow-up.
        </p>
        <p>
        </p>
        <p>
         Further details on SILND for inguinal staging in patients with carcinoma of the penis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Superficial inguinal lymph node dissection (ILND)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8904433">
         <span class="h3">
          Treatment of low-risk disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of inguinal metastases among men with low-risk disease ranges from 0 to 18 percent [
         <a href="#rid37">
          37,41,42,55
         </a>
         ]. We agree with recommendations from the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) and offer these men surveillance rather than surgical staging, provided they are able to comply with follow-up recommendations  (
         <a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Clinically negative inguinal examination'
         </a>
         .)
        </p>
        <p>
         Men who are unable or unwilling to proceed with surveillance should undergo bilateral inguinal node staging by DSNB or SILND. Based on available data, for men with cN0 status, we also believe that minimally invasive RAIL or LAP inguinal removal in experienced hands is a reasonable approach [
         <a href="#rid49">
          49-52
         </a>
         ]. Additional treatment is based upon the results of that staging. (See
         <a class="local">
          'Treatment of high-risk disease'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Dynamic sentinel node biopsy (DSNB)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8904447">
         <span class="h3">
          Treatment of high-risk disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Men at high risk should undergo either DSNB or open SILND. Both RAIL and LAP approaches are also acceptable (provided the expertise and the facilities are available)  (
         <a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Clinically negative inguinal examination'
         </a>
         .)
        </p>
        <p>
         Further treatment of the regional nodes is guided by the pathologic findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with negative inguinal nodes following either open bilateral SILND, minimally invasive LND, or DSNB require no further therapy. We recommend posttreatment surveillance. (See
         <a class="local">
          'Posttreatment surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with one pathologically involved inguinal node and without extranodal extension require a complete ipsilateral inguinal LND. (See
         <a class="local">
          'Therapeutic inguinal node dissection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with two or more pathologically involved inguinal nodes, or with one involved node and evidence of extranodal extension should undergo a therapeutic ipsilateral inguinal LND and unilateral or bilateral pelvic LND [
         <a href="#rid56">
          56
         </a>
         ]. Adjuvant therapy (eg, chemotherapy, radiation, or chemoradiation) should be offered. (See
         <a class="local">
          'Therapeutic inguinal node dissection'
         </a>
         below and
         <a class="local">
          'Pelvic node dissection'
         </a>
         below and
         <a class="local">
          'Adjuvant therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9746503">
         <span class="h2">
          Clinically suspicious examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         We stratify our approach to men who present with palpable inguinal adenopathy based upon the clinical examination and/or imaging, and the results of FNA  (
         <a class="graphic graphic_algorithm graphicRef114728" href="/z/d/graphic/114728.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Fine needle aspiration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9746563">
         <span class="h3">
          Enlarged, unilateral inguinal node present
         </span>
         <span class="headingEndMark">
          —
         </span>
         For men who present with a unilateral, solitary inguinal node &lt;4 cm in size, we suggest FNA of the palpable inguinal node.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the FNA is positive, a complete (ie, superficial and deep) inguinal LND should be performed as it may provide therapeutic benefit in men with pathologically involved lymph nodes. (See
         <a class="local">
          'Therapeutic inguinal node dissection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We prefer an open surgical approach, given the limited experience and follow-up using RAIL or LAP techniques in the setting of clinically positive nodes. However, minimally invasive (eg, RAIL or LAP) surgical techniques are an alternative option in centers with appropriate expertise.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A therapeutic open fascial-sparing, saphenous-sparing approach has also been reported with longer-term follow-up [
         <a href="#rid57">
          57
         </a>
         ]. This dissection is similar to SILND because it spares the fascia lata of the thigh and preserves the saphenous vein, but it also obviates the need for frozen sections because it removes the deep nodes within the fossa ovalis around the femoral vessels. In one study evaluating this approach, 104 patients underwent 201 inguinal dissections for cN0-cN2 (minimal disease). At a median follow-up of 36 months, only a single inguinal recurrence was noted [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the FNA is negative, we proceed with an ipsilateral SILND with frozen section pathology performed at the time of the procedure. In this setting, a minimally invasive (ie, RAIL or LAP) approach is also reasonable in the hands of experienced surgeons.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients should also undergo a staging procedure on the contralateral clinically node-negative side, as bilateral inguinal drainage from the primary tumor is common [
         <a href="#rid58">
          58
         </a>
         ]. Options for such staging procedures include SILND (using either an open or minimally invasive [ie, RAIL or LAP] approach) or DSNB.
        </p>
        <p>
        </p>
        <p>
         Based on the results at inguinal LND, we suggest:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No further treatment for patients with a single positive inguinal lymph node and no evidence of extranodal extension. (See
         <a class="local">
          'Posttreatment surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pelvic LND if two or more pathologically involved nodes are identified or if extranodal extension is seen on frozen section or final pathology. This information defines patients at higher risk for inguinal node recurrence and for pelvic lymph node metastases. Such patients are candidates for adjuvant therapy (either chemotherapy, radiation, or chemoradiation). (See
         <a class="local">
          'Pelvic node dissection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9746975">
         <span class="h3">
          Multiple or bilateral inguinal nodes present
         </span>
         <span class="headingEndMark">
          —
         </span>
         For men with evidence of multiple or bilateral palpable inguinal nodes based upon clinical examination or imaging, we suggest FNA as the initial staging evaluation  (
         <a class="graphic graphic_algorithm graphicRef114729" href="/z/d/graphic/114729.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Fine needle aspiration'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the FNA is negative, we recommend a superficial inguinal LND with intraoperative frozen sections to determine the pathologic stage. If pathology from the inguinal LND is negative, surveillance is appropriate; if pathology identifies metastatic disease, complete inguinal LND is indicated, and potentially pelvic LND if multiple nodes are positive or extranodal extension is found. Alternatively, if intraoperative frozen sections cannot be performed or are felt to be unreliable, a fascial-sparing dissection is an alternative approach to SILND [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2959.html" rel="external">
          "Carcinoma of the penis: Clinical presentation, diagnosis, and staging", section on 'Superficial inguinal lymph node dissection (ILND)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the FNA is positive, the patient likely has at least stage N2 metastatic penile cancer and is at risk for treatment failure with surgery alone [
         <a href="#rid34">
          34,35
         </a>
         ]. We suggest neoadjuvant chemotherapy followed by complete inguinal and pelvic LND [
         <a href="#rid59">
          59,60
         </a>
         ]. An alternative approach would consist of an upfront therapeutic inguinal and pelvic LND, provided the patient is a surgical candidate. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         below and
         <a class="local">
          'Adjuvant therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H461757845">
         <span class="h3">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with proven inguinal metastases should undergo an open therapeutic inguinal LND. Patients with clinical or biopsy-proven N2 to N3 disease on inguinal LND are candidates for neoadjuvant chemotherapy followed by ipsilateral (or bilateral) pelvic LND. Patients with pelvic adenopathy on imaging should also be offered neoadjuvant chemotherapy. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H461757611">
         <span class="h4">
          Therapeutic inguinal node dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         A therapeutic inguinal LND is the most reliable means of establishing the presence or absence of nodal metastases and simultaneously treating any disease that is present [
         <a href="#rid61">
          61,62
         </a>
         ]. For men with microscopically involved nodes, long-term cure may be achieved in as many as 90 percent using this approach [
         <a href="#rid44">
          44,63,64
         </a>
         ]. In the largest series, 65 patients who were surgically treated for stage I to III penile cancer were followed for a minimum of five years [
         <a href="#rid63">
          63
         </a>
         ]. More patients who underwent surgical treatment of the primary lesion followed by inguinal lymphadenectomy remained disease-free compared with those who underwent surgical treatment of the primary lesion alone for stage II (88 versus 38 percent) or stage III (66 versus 0 percent) disease.
        </p>
        <p>
         As noted above, an inguinal LND can be performed as an open procedure or accomplished using a RAIL or LAP technique, if the expertise is available. RAIL or LAP techniques offer the potential of removing all inguinal nodes while minimizing complications such as wound infection or dehiscence. However, additional comparative studies with long-term follow-up comparing these minimally invasive techniques with a more traditional open approach are needed before they can be recommended as the standard of care, especially in the setting of cN2-cN3 penile carcinoma [
         <a href="#rid50">
          50,52
         </a>
         ]. (See
         <a class="local">
          'Clinically suspicious examination'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H461757704">
         <span class="h4">
          Pelvic node dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of multiple pathologically identified inguinal nodes or of extranodal extension increases the risk for pelvic lymph node involvement. Therefore, in the presence of multiple pathologically involved inguinal nodes or extranodal extension in a single lymph node, we proceed with a prophylactic pelvic LND. The pelvic LND can either be performed at the time of the open inguinal LND or in a delayed fashion using either open, laparoscopic, or robotic techniques.
        </p>
        <p>
         While one series suggests that men with a single inguinal node involved and without evidence of extracapsular extension rarely have pelvic node involvement [
         <a href="#rid65">
          65
         </a>
         ], another series reported that the risk of pelvic node involvement ranges from 22 percent, if one to three nodes are positive, to 57 percent, if more than three inguinal nodes are involved [
         <a href="#rid66">
          66
         </a>
         ]. However, whether pelvic LND influences survival outcomes is not clear.
        </p>
        <p class="headingAnchor" id="H133644063">
         <span class="h1">
          NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED OR UNRESECTABLE DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H1430013920">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Men who present with an unresectable primary tumor, bulky inguinal adenopathy, bilateral inguinal node involvement, or pelvic adenopathy on imaging have a low probability of cure with surgery alone or may not be immediately resectable. In this setting, our approach is to use neoadjuvant chemotherapy [
         <a href="#rid59">
          59,60,67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3054339478">
         <span class="h2">
          TIP chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The objective of neoadjuvant chemotherapy is to improve disease-free and overall survival following subsequent surgical therapy. We consider the TIP regimen to be the standard in the neoadjuvant setting. The TIP regimen consists of
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (T; 175 mg/m
         <sup>
          2
         </sup>
         administered over three hours on day 1),
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         (I; 1200 mg/m
         <sup>
          2
         </sup>
         on days 1 to 3), and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (P; 25 mg/m
         <sup>
          2
         </sup>
         on days 1 to 3) at three to four-week intervals for four cycles.
        </p>
        <p>
         This treatment approach is based on a phase II study as well as an observational cohort study with extended follow-up of 61 men with advanced penile cancer receiving neoadjuvant chemotherapy [
         <a href="#rid59">
          59,60
         </a>
         ]. Among patients who received neoadjuvant TIP, an objective response was noted in 39 of 60 patients evaluable for response (65 percent), with 10 patients achieving pN0 status at surgical resection [
         <a href="#rid60">
          60
         </a>
         ]. The five-year overall survival rate was higher among patients achieving an objective response than among those with progressive disease during chemotherapy (50 versus 8 percent) [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         All men who have a clinical response to treatment and those with stable disease should undergo surgical resection. Those with tumor progression or unresectable disease despite neoadjuvant chemotherapy should be offered palliative therapy. The approach to men in the latter situation is similar to that for men with metastatic disease. (See
         <a class="local">
          'Distant metastatic disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H22657471">
         <span class="h1">
          ADJUVANT THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H445739799">
         <span class="h2">
          Adjuvant chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is limited evidence regarding the role of adjuvant therapy in men with penile carcinoma. However, given the suggested benefit of neoadjuvant chemotherapy for men with locally advanced or unresectable disease, we suggest adjuvant chemotherapy for men who were not treated in the neoadjuvant setting if any of the following risk factors for disease relapse are present [
         <a href="#rid68">
          68,69
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pelvic lymph node involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal extension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral inguinal node involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More than three positive nodes
        </p>
        <p>
        </p>
        <p>
         For patients receiving adjuvant chemotherapy, we suggest four cycles of the TIP regimen (
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ). We favor TIP through extrapolation from the neoadjuvant experience and because the prognosis for recurrent, metastatic disease is so poor. However, other cisplatin-based regimens have been utilized based on their activity in the metastatic setting. There is insufficient evidence to establish a standard adjuvant strategy, whether with radiotherapy, chemoradiation, or a cisplatin-based regimen. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         above and
         <a class="local">
          'Distant metastatic disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H445739805">
         <span class="h2">
          Adjuvant radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest adjuvant RT, either as a single agent or concurrent chemoradiation, to the inguinal and pelvic regions for patients who have viable disease with extranodal extension and/or disease in bilateral lymph nodes on surgical staging, or for high-risk patients who refuse or are not candidates for adjuvant chemotherapy. For patients who receive chemoradiation, options for chemotherapy include
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         plus
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         .
        </p>
        <p>
         Adjuvant RT to the inguinal or pelvic regions (either as a single agent or concurrent chemoradiation) may be useful but has not been rigorously evaluated and is controversial [
         <a href="#rid70">
          70
         </a>
         ]. Our treatment approach is generally consistent with the National Comprehensive Cancer Network guidelines, which recommend its use in the post-ILND setting with adverse pathologic findings, and based upon its potential efficacy in other squamous tumors. However, our approach differs from the European Association of Urology (EAU) guidelines panel. The EAU guidelines do not recommend its use in the absence of prospective data, the relatively sparse literature on its efficacy in penile cancer, and the potential for adverse side effects [
         <a href="#rid71">
          71
         </a>
         ]. This strategy requires evaluation in a prospective clinical trial. (See
         <a class="local">
          'Investigational options'
         </a>
         below.)
        </p>
        <p>
         Data supporting the use of adjuvant RT in penile cancer are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, women with pathologically node-positive vulvar cancer (a disease site with similar lymphatic drainage to penile cancer) were randomly assigned to postoperative pelvic and groin radiation (45 to 50 Gy, n = 59) or to ipsilateral pelvic node resection (n = 55) after radical vulvectomy and inguinal lymphadenectomy [
         <a href="#rid72">
          72
         </a>
         ]. In this trial, adjuvant RT was found to be efficacious in terms of both local control and cancer-specific survival outcomes. Thus, to the extent that metastatic inguinal and pelvic nodes due to penile cancer behave in a similar fashion to those due to vulvar cancer, adjuvant RT to the inguinal and pelvic regions might be an alternative to pelvic lymph node dissection among those with pN2 to N3 disease on inguinal lymph node dissection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series of men with penile cancer from the Netherlands, adjuvant inguinal RT was routinely given when either extranodal extension or two or more inguinal metastases were present [
         <a href="#rid73">
          73
         </a>
         ]. Among the patients with extranodal extension, five-year survival was 42 percent, which is greater than that in a separate series reporting extranodal extension without adjuvant RT [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The addition of chemotherapy to RT has been used effectively in patients with penile cancer and other squamous tumor sites such as anal, cervical, and vulvar cancers [
         <a href="#rid74">
          74-76
         </a>
         ]. Although most studies demonstrated the efficacy of chemoradiation alone (ie, definitive chemoradiation) or before surgery (induction chemoradiation) [
         <a href="#rid76">
          76,77
         </a>
         ], chemoradiation as a combined strategy could also further improve survival when administered in the adjuvant setting, extrapolating from these studies. Data supporting the use of chemoradiation in penile cancer are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One observational study evaluated definitive chemoradiation in six patients with penile cancer who had both intact primary tumors and N2-3 nodal disease [
         <a href="#rid77">
          77
         </a>
         ]. Patients received either weekly
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or two cycles of
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         plus
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         along with radiation to the primary tumor as well as involved and uninvolved inguinal and pelvic nodal basins. At a median follow-up of 7.2 years, four of six patients were recurrence free and two developed primary tumor recurrence. There were no nodal failures and none developed distant metastases [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         These initial data in penile cancer are consistent with prior observational data from the vulvar squamous carcinoma experience. In one study, 38 of 40 patients with vulvar carcinoma and nodal disease treated with induction chemoradiation were subsequently rendered resectable [
         <a href="#rid76">
          76
         </a>
         ]. Among the 37 patients who received surgery, 15 (40 percent) had histologically negative disease in the lymph nodes on postoperative pathology.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1419912646">
         <span class="h1">
          INVESTIGATIONAL OPTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited prospective data studies for neoadjuvant or adjuvant therapeutic strategies in advanced penile cancer. An ongoing global clinical trial, the International Penile Advanced Cancer Trial (InPACT;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02305654&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOVYNz3GeThqnSD5OTA854CnvIBZyoAM3AGK5ZzWYCNsA%3D%3D&amp;TOPIC_ID=16866" target="_blank">
          NCT02305654
         </a>
         ) will prospectively determine the relative benefits and sequencing of surgery, chemotherapy, and chemoradiation in the management of patients with penile cancer who present with palpable or radiologically evident inguinal lymph node metastases [
         <a href="#rid78">
          78
         </a>
         ]. InPACT will address the following questions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is there a role for neoadjuvant therapy and, if so, which of two options (chemotherapy or chemoradiation) prior to surgery produces superior outcomes?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients whose inguinal node histology predicts high risk of recurrence, does prophylactic pelvic lymph node dissection plus chemoradiation to the inguinal and pelvic fields improve survival compared with chemoradiation alone?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H681108">
         <span class="h1">
          POSTTREATMENT SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, most invasive primary penile carcinomas were treated with radical surgery, and the frequency of local recurrences was low. With the increasing utilization of penile-sparing therapies, the incidence of local recurrence appears to have increased [
         <a href="#rid10">
          10
         </a>
         ]. Many of those with a locoregional relapse may be treated with curative intent using aggressive locoregional therapy. (See
         <a class="local">
          'Localized recurrence'
         </a>
         below.)
        </p>
        <p>
         All men treated for penile carcinoma require close follow-up. Although there are no high-quality data looking at outcomes to inform an optimal follow-up paradigm, posttreatment surveillance guidelines have been published by the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid41">
          41,42
         </a>
         ]. While both are suitable, our posttreatment surveillance is consistent with NCCN guidelines:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who underwent an
         <strong>
          organ-sparing procedure
         </strong>
         (eg, wide excision, glansectomy, Mohs micrographic surgery, or laser ablation), physical examination should be carried out every three months for the first two years, every six months during years 3 to 5, then yearly up to 10 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who underwent a
         <strong>
          partial or total penectomy
         </strong>
         , physical examination should be performed every six months for the first two years, then every 12 months during years 3 to 5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who did not undergo inguinal lymphadenectomy (ie, opted for
         <strong>
          surveillance
         </strong>
         ), physical examination should be carried out every two to three months for the first two years, every four months during year 3, then every six months in years 4 and 5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with
         <strong>
          pN0
         </strong>
         disease following a lymph node dissection (LND), physical examination should be performed every four months for the first two years, every six months during year 3, then yearly during years 4 and 5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who underwent an LND with pathologically positive nodes (pN+) are at high risk for local and/or distant recurrence. These patients should undergo follow-up with physical examination every three months for the first two years, every four months during year 3, then every six months in years 4 and 5. We would recommend an abdominal and pelvic computed tomography (CT) scan during all visits during the first two years for node-positive patients. Imaging studies are optional after this period.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H133643934">
         <span class="h1">
          RECURRENT OR METASTATIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Men with a history of penile cancer are at risk for both localized recurrence and distant metastases, and up to 30 percent of all patients will subsequently recur [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         The outcomes of men following recurrence were evaluated in one study that included 314 men treated for penile cancer between 1942 and 2012 [
         <a href="#rid80">
          80
         </a>
         ]. The median time to recurrence was 10.5 months, and 35, 38, and 10 percent of these recurred locally, regionally, and distantly, respectively. Time from the initial surgery to recurrence was significantly associated with shorter overall survival. In addition, factors significantly associated with an increased risk of cancer-specific mortality included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymph node metastases at initial presentation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regional recurrence
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distant recurrence
        </p>
        <p>
        </p>
        <p>
         For men who recur, treatment can be stratified by the type of recurrence. This approach to treatment is discussed below.
        </p>
        <p class="headingAnchor" id="H6624224">
         <span class="h2">
          Localized recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following treatment, men are at risk for a penile recurrence (if not treated with penile amputation) or an inguinal recurrence.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For men who have a penile recurrence, we proceed with a penile amputation in most cases. However, whether a partial or total amputation is required depends on the location and extent of the tumor recurrence. Occasionally, carefully selected patients (ie, those with small and low-grade recurrences) may be treated with a second organ-preserving strategy. Overall, disease-specific survival is good when local recurrence is promptly recognized and appropriately treated [
         <a href="#rid1">
          1,79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For men who experience an inguinal recurrence, the prognosis is poor. We suggest multimodality treatment using either chemotherapy plus surgery or chemoradiation (with or without surgery) [
         <a href="#rid1">
          1,33,79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Any patient undergoing resection of a recurrent penile tumor should also undergo nodal reevaluation. A prophylactic inguinal staging procedure (ie, superficial or modified dissection or dynamic sentinel node biopsy) is a reasonable treatment option in cases with an invasive recurrent tumor where a prior lymph node dissection was not performed.
        </p>
        <p>
         For men with localized recurrence and fixed groin nodes or high local tumor burden not amenable to surgical resection, treatment is palliative. However, chemotherapy-naïve patients should be considered for neoadjuvant chemotherapy followed by surgery with curative intent. Radiation therapy (RT) can alleviate pressure associated with tumor compression and improve quality of life for men with incurable disease [
         <a href="#rid81">
          81
         </a>
         ]. Otherwise, for men who wish to receive further treatment and are deemed good candidates for systemic treatment, we suggest palliative chemotherapy. (See
         <a class="local">
          'Distant metastatic disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H118145232">
         <span class="h2">
          Distant metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients presenting with or who develop disseminated disease (M1), we individualize treatment based on the patient's performance status and symptoms [
         <a href="#rid82">
          82
         </a>
         ]. For men with a good performance status (eg, Karnofsky performance status &gt;80  (
         <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">
          table 2
         </a>
         )), we offer platinum-based chemotherapy or enrollment in a clinical trial whenever possible.
        </p>
        <p>
         For all others, we prefer best supportive care; some of these patients may also qualify for palliative platinum-based chemotherapy such as
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         .
        </p>
        <p>
         The role of immunotherapy, including checkpoint inhibitors, is not established for advanced penile cancer except in cases with DNA mismatch repair deficiency or microsatellite instability. (See
         <a class="local">
          'Immune checkpoint inhibitors'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4104435749">
         <span class="h3">
          Chemotherapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy
         </strong>
         – Chemotherapy results in overall response rates of up to 30 to 38 percent in patients with distant metastatic penile carcinoma [
         <a href="#rid83">
          83-85
         </a>
         ]. A 2010 review of the literature concluded that cisplatin-containing regimens were most active [
         <a href="#rid81">
          81
         </a>
         ]. Although
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         had a similar level of activity, it was associated with a high incidence of clinically significant pulmonary toxicity and should not be used [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Active combination regimens in penile carcinoma have been identified, but there are no randomized clinical trials to inform a preferred regimen. The choice of the regimen should be based upon patient and provider preference after an individualized consideration of their potential toxicities. Active regimens include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (TIP). (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         (70 to 80 mg/m
         <sup>
          2
         </sup>
         on day 1) plus
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (800 to 1000 mg/m
         <sup>
          2
         </sup>
         per day continuous infusion on days 1 to 4 or 2 to 5) every three to four weeks [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         (175 mg/m
         <sup>
          2
         </sup>
         on day 1) plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (area under curve = 6 on day 1) given every three to four weeks (for patients who are ineligible for
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent therapy
         </strong>
         – For patients who progress after their initial chemotherapy, the prognosis is poor, with a median survival of less than six months [
         <a href="#rid88">
          88
         </a>
         ]. Whenever possible, patients with chemotherapy-recurrent disease should be offered participation in clinical trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other potentially active agents include
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         and
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , which target the epidermal growth factor receptor (EGFR) [
         <a href="#rid89">
          89,90
         </a>
         ]; responses have been noted with these agents either alone or in combination with chemotherapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3141993658">
         <span class="h3">
          Immune checkpoint inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of immune checkpoint inhibitors (ICIs) is not established in patients with metastatic penile carcinoma, and this approach remains experimental. In early phase clinical trials, limited responses have been seen with
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         with or without radiation therapy [
         <a href="#rid91">
          91
         </a>
         ],
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         [
         <a href="#rid92">
          92
         </a>
         ], and
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (with or without
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         ) [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H760194087">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of the primary tumor
         </strong>
         – Management of the primary tumor is guided by tumor location, size, and AJCC eighth edition Tumor, Node, Metastasis (TNM) stage  (
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef114726" href="/z/d/graphic/114726.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Treatment of the primary tumor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tis, Ta, T1-T2 disease
         </strong>
         – For men with stage Tis, Ta, or T1 penile tumors  (
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         ), we recommend limited excision rather than penile amputation (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ), as these patients have a good prognosis with treatment and are at a low risk of recurrence. Some men with distal, T2, glanular penile lesions are also candidates for glans resection or removal alone, sparing the corporal bodies. (See
         <a class="local">
          'Tumors with a low risk of recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Organ-preserving strategies approaches
         </strong>
         – Alternative organ-preserving strategies include topical therapy (Tis), partial excision of the glans penis (Ta, T1, some T2), Mohs micrographic surgery (Ta, T1, some T2), resection of the glans penis skin and subepithelial connective tissue (ie, glans resurfacing [Tis]), laser ablation (Tis), and radiation therapy (RT; T1 or distal T2, tumors &lt;4 cm). (See
         <a class="local">
          'Alternative organ-preserving strategies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T2-T4 disease
         </strong>
         – Men with bulky stage T2 to T4 tumors  (
         <a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">
          table 1
         </a>
         ) are at higher risk of recurrence with organ-preserving strategies. For these men, we suggest penile amputation to obtain a negative surgical margin rather than more limited excisional strategies (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Penile amputation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to the regional lymph nodes
         </strong>
         – Management of the regional lymph nodes is based upon clinical examination and the histology of the primary tumor. (See
         <a class="local">
          'Approach to the regional nodes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically negative lymph nodes
         </strong>
         – For men with a clinically negative inguinal examination, we stratify our approach to the regional nodes based upon whether there is a low or high risk of nodal involvement  (
         <a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">
          algorithm 2
         </a>
         ) (see
         <a class="local">
          'Clinically negative examination'
         </a>
         above and
         <a class="local">
          'Risk stratification'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low risk of nodal involvement
         </strong>
         – For men with Tis, Ta, or T1a tumors, we suggest surveillance, provided they are able to comply with posttreatment surveillance (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Treatment of low-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For men who are unable or unwilling to proceed with surveillance, we suggest an inguinal node evaluation using dynamic sentinel node biopsy (DSNB), provided the expertise is available (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If DSNB cannot be performed, we proceed with a superficial inguinal lymph node dissection (SILND) using minimally invasive techniques such as laparoscopic (LAP) or robotic-assisted inguinal lymphadenectomy (RAIL).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk of nodal involvement
         </strong>
         – For men with T1b or T2 to T4 tumors, a bilateral, superficial inguinal lymph node dissection (LND) or RAIL or LAP techniques, or DSNB are all acceptable staging techniques. (See
         <a class="local">
          'Treatment of high-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For men with up to one pathologically involved lymph node (based upon frozen section histology) without extranodal extension, we suggest a therapeutic inguinal LND performed either at the time of lymphadenectomy (if not already completed) or subsequent to DSNB (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For men with two or more pathologically involved nodes or with extranodal extension identified (based upon frozen section), we suggest a therapeutic inguinal LND plus pelvic LND (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Adjuvant therapy (ie, chemotherapy, radiation, or chemoradiation) should be offered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest surveillance for men who have a negative DSNB or superficial inguinal LND (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ipsilateral, clinically positive lymph node &lt;4 cm
         </strong>
         – For men with an ipsilateral, clinically suspicious examination of the groin, we suggest a fine needle aspiration (FNA)  (
         <a class="graphic graphic_algorithm graphicRef114728" href="/z/d/graphic/114728.html" rel="external">
          algorithm 3
         </a>
         ) (see
         <a class="local">
          'Enlarged, unilateral inguinal node present'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the FNA is positive, we suggest an ipsilateral, therapeutic inguinal LND (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the FNA is negative, we proceed with an ipsilateral SILND with intraoperative frozen sections or fascial-sparing dissection for further evaluation. LAP or RAIL procedures are suitable alternatives in experienced hands.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All men should also undergo a contralateral inguinal staging procedure (ie, SILND or RAIL or LAP techniques, or DSNB; based upon experience).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For men with two or more pathologically involved nodes (based upon biopsy) or if the presence of extranodal extension is proven, we suggest
         <em>
         </em>
         ipsilateral pelvic lymphadenectomy followed by adjuvant therapy (either chemotherapy, radiation, or chemoradiation) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Clinical trial enrollment is encouraged, if available. (See
         <a class="local">
          'Investigational options'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple or bilateral clinically positive lymph nodes
         </strong>
         – For men with multiple or bilateral palpable inguinal nodes, we suggest an FNA  (
         <a class="graphic graphic_algorithm graphicRef114729" href="/z/d/graphic/114729.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="local">
          'Multiple or bilateral inguinal nodes present'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the FNA is negative, we proceed with a unilateral or bilateral (as appropriate) superficial LND with intraoperative frozen sections for further evaluation. Other acceptable approaches on this setting include fascial sparing lymphadenectomy, LAP, or RAIL techniques.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the FNA is positive, we suggest neoadjuvant chemotherapy followed by surgery rather than an initial definitive surgical approach (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). An alternative strategy includes surgical resection followed by adjuvant therapy or clinical trial enrollment. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Locally advanced or unresectable disease
         </strong>
         – For men with unresectable penile carcinoma, bulky adenopathy, or evidence of pelvic nodal involvement, neoadjuvant chemotherapy should be given for downstaging. Clinical trial enrollment is encouraged in this setting as well. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are candidates for neoadjuvant chemotherapy, we suggest four cycles of TIP (
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Definitive surgery should be performed in men who have an objective response to treatment, and it may also be an option in men with stable/resectable disease. (See
         <a class="local">
          'Neoadjuvant chemotherapy for locally advanced or unresectable disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for adjuvant chemotherapy
         </strong>
         – We suggest adjuvant chemotherapy for men who did not previously receive neoadjuvant chemotherapy and with high-risk factors for relapse (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Extrapolating from the neoadjuvant experience, we suggest four cycles of TIP (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Adjuvant chemotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for adjuvant radiation
         </strong>
         – For men at high risk of recurrence who are not candidates for adjuvant chemotherapy, we suggest adjuvant RT, either as a single agent or concurrent chemoradiation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For patients who receive chemoradiation, options for chemotherapy include weekly
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         plus
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         . (See
         <a class="local">
          'Adjuvant radiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Locally recurrent disease
         </strong>
         – For men who experience a local recurrence, we suggest that a partial or total penile amputation be performed (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). In addition, based on the grade and stage of the local recurrence, the inguinal region should be reevaluated and treated as appropriate. (See
         <a class="local">
          'Localized recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastatic disease
         </strong>
         – For men with or who develop disseminated disease (M1), we individualize treatment based on the patient's performance status and symptoms. For those with a good performance status, we offer platinum-based chemotherapy or enrollment in a formal clinical trial, whenever possible. (See
         <a class="local">
          'Distant metastatic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Philippou P, Shabbir M, Malone P, et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol 2012; 188:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sri D, Sujenthiran A, Lam W, et al. A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int 2018; 122:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal A, Pai D, Ananthakrishnan N, et al. The histological extent of the local spread of carcinoma of the penis and its therapeutic implications. BJU Int 2000; 85:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minhas S, Manseck A, Watya S, Hegarty PK. Penile cancer--prevention and premalignant conditions. Urology 2010; 76:S24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alnajjar HM, Lam W, Bolgeri M, et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 2012; 62:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone A, Inman B, Spiess PE. Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors. Eur Urol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skeppner E, Windahl T, Andersson SO, Fugl-Meyer KS. Treatment-seeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma. Eur Urol 2008; 54:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tietjen DN, Malek RS. Laser therapy of squamous cell dysplasia and carcinoma of the penis. Urology 1998; 52:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frimberger D, Hungerhuber E, Zaak D, et al. Penile carcinoma. Is Nd:YAG laser therapy radical enough? J Urol 2002; 168:2418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lont AP, Gallee MP, Meinhardt W, et al. Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol 2006; 176:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meijer RP, Boon TA, van Venrooij GE, Wijburg CJ. Long-term follow-up after laser therapy for penile carcinoma. Urology 2007; 69:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang DH, Yan S, Ottenhof SR, et al. Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urol Oncol 2018; 36:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadway P, Corbishley CM, Watkin NA. Total glans resurfacing for premalignant lesions of the penis: initial outcome data. BJU Int 2006; 98:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shabbir M, Muneer A, Kalsi J, et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol 2011; 59:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Kelly F, Lonergan P, Lundon D, et al. A Prospective Study of Total Glans Resurfacing for Localized Penile Cancer to Maximize Oncologic and Functional Outcomes in a Tertiary Referral Network. J Urol 2017; 197:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shindel AW, Mann MW, Lev RY, et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol 2007; 178:1980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol 2009; 27:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escande A, Haie-Meder C, Mazeron R, et al. Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. Int J Radiat Oncol Biol Phys 2017; 99:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol 1997; 32:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delannes M, Malavaud B, Douchez J, et al. Iridium-192 interstitial therapy for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 1992; 24:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerbaulet A, Lambin P. Radiation therapy of cancer of the penis. Indications, advantages, and pitfalls. Urol Clin North Am 1992; 19:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelley CD, Arthur K, Rogoff E, Grabstald H. Radiation therapy of penile cancer. Urology 1974; 4:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushal V, Sharma SC. Carcinoma of the penis. A 12-year review. Acta Oncol 1987; 26:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gotsadze D, Matveev B, Zak B, Mamaladze V. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol 2000; 38:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarin R, Norman AR, Steel GG, Horwich A. Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. Int J Radiat Oncol Biol Phys 1997; 38:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soria JC, Fizazi K, Piron D, et al. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol 1997; 8:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solsona E, Bahl A, Brandes SB, et al. New developments in the treatment of localized penile cancer. Urology 2010; 76:S36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minhas S, Kayes O, Hegarty P, et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005; 96:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietrzak P, Corbishley C, Watkin N. Organ-sparing surgery for invasive penile cancer: early follow-up data. BJU Int 2004; 94:1253.
          </a>
         </li>
         <li class="breakAll">
          Brown G, Khadra A, Abdelraheem A, et al. Predictors of penile cancer recurrence following conservative surgical resection (abstract 995). Eur Urol Suppl 2009; 8:369.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ornellas AA, Kinchin EW, Nóbrega BL, et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol 2008; 97:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bickell M, Beilan J, Wallen J, et al. Advances in Surgical Reconstructive Techniques in the Management of Penile, Urethral, and Scrotal Cancer. Urol Clin North Am 2016; 43:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettaway CA, Pagilaro L. Penile squamous carcinoma. Part II: Contemporary management of the inguinal region. AUA Update Series 2012; 31:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marconnet L, Rigaud J, Bouchot O. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol 2010; 183:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006; 93:133.
          </a>
         </li>
         <li class="breakAll">
          Pettaway CA, Srigley JR, Brookland RK, et al. Penis. In: AJCC Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, New York 2017. p.701.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun M, Djajadiningrat RS, Alnajjar HM, et al. Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU Int 2015; 116:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ficarra V, Akduman B, Bouchot O, et al. Prognostic factors in penile cancer. Urology 2010; 76:S66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakies Ch, Lopez-Beltran A, Comperat E, et al. Reproducibility of histopathologic tumor grading in penile cancer--results of a European project. Virchows Arch 2014; 464:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velazquez EF, Ayala G, Liu H, et al. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol 2008; 32:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakenberg OW, Compérat EM, Minhas S, et al. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015; 67:142.
          </a>
         </li>
         <li class="breakAll">
          National Comoprehensive Cancer Network (NCCN) guidelines. Penile cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (Accessed on April 18, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leijte JA, Hughes B, Graafland NM, et al. Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis. J Clin Oncol 2009; 27:3325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coblentz TR, Theodorescu D. Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penis. J Urol 2002; 168:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol 2009; 27:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catalona WJ. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol 1988; 140:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colberg JW, Andriole GL, Catalona WJ. Long-term follow-up of men undergoing modified inguinal lymphadenectomy for carcinoma of the penis. Br J Urol 1997; 79:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien JS, Perera M, Manning T, et al. Penile Cancer: Contemporary Lymph Node Management. J Urol 2017; 197:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Master VA, Jafri SM, Moses KA, et al. Minimally invasive inguinal lymphadenectomy via endoscopic groin dissection: comprehensive assessment of immediate and long-term complications. J Urol 2012; 188:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwentner C, Todenhöfer T, Seibold J, et al. Endoscopic inguinofemoral lymphadenectomy--extended follow-up. J Endourol 2013; 27:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matin SF, Cormier JN, Ward JF, et al. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 2013; 111:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh A, Jaipuria J, Goel A, et al. Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis. J Urol 2018; 199:1518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gkegkes ID, Minis EE, Iavazzo C. Robotic-assisted inguinal lymphadenectomy: a systematic review. J Robot Surg 2019; 13:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel KN, Salunke A, Bakshi G, et al. Robotic-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) and Video-Endoscopic Inguinal Lymphadenectomy (VEIL) versus Open Inguinal Lymph-Node Dissection (OILND) in carcinoma of penis: Comparison of perioperative outcomes, complications and oncological outcomes. A systematic review and meta-analysis. Urol Oncol 2022; 40:112.e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li ZS, Yao K, Chen P, et al. Modification of N staging systems for penile cancer: a more precise prediction of prognosis. Br J Cancer 2015; 112:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lont AP, Kroon BK, Gallee MP, et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007; 177:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao K, Zou ZJ, Li ZS, et al. Fascia lata preservation during inguinal lymphadenectomy for penile cancer: rationale and outcome. Urology 2013; 82:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiess PE, Izawa JI, Bassett R, et al. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 2007; 177:2157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28:3851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int 2016; 117:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDougal WS. Carcinoma of the penis: improved survival by early regional lymphadenectomy based on the histological grade and depth of invasion of the primary lesion. J Urol 1995; 154:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyns CF, van Vollenhoven P, Steenkamp JW, et al. Carcinoma of the penis--appraisal of a modified tumour-staging system. Br J Urol 1997; 80:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDougal WS, Kirchner FK Jr, Edwards RH, Killion LT. Treatment of carcinoma of the penis: the case for primary lymphadenectomy. J Urol 1986; 136:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroon BK, Horenblas S, Lont AP, et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005; 173:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horenblas S, van Tinteren H, Delemarre JF, et al. Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes. J Urol 1993; 149:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol 1993; 72:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djajadiningrat RS, Bergman AM, van Werkhoven E, et al. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer 2015; 13:44.
          </a>
         </li>
         <li class="breakAll">
          NCCN Guidelines Version 1.2012: Penile Cancer. http://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (Accessed on June 14, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma P, Djajadiningrat R, Zargar-Shoshtari K, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol 2015; 33:496.e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson R, Marconi L, MacPepple E, et al. Risks and benefits of adjuvant radiotherapy after inguinal lymphadenectomy and node-positive penile cancer: a systematic review by the European Association of Urology Penile Cancer Guidelines panel. Eur Urol 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson R, Marconi L, MacPepple E, et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. Eur Urol 2018; 74:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009; 114:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graafland NM, van Boven HH, van Werkhoven E, et al. Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol 2010; 184:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stehman FB, Ali S, Keys HM, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 2007; 197:503.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2000; 48:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McComas K, Agarwal N, Bowen G, et al. Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer 2020; 18:e573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canter DJ, Nicholson S, Watkin N, et al. The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status. Eur Urol Focus 2019; 5:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieken M, Djajadiningrat RS, Kluth LA, et al. Predictors of cancer-specific mortality after disease recurrence in patients with squamous cell carcinoma of the penis. Eur Urol 2014; 66:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010; 76:S58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connell CF, Berger NA. Management of advanced squamous cell carcinoma of the penis. Urol Clin North Am 1994; 21:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999; 161:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lorenzo G, Federico P, Buonerba C, et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011; 60:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012; 110:E661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bermejo C, Busby JE, Spiess PE, et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Pettaway CA, Pagliaro LC. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology 2015; 85:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Necchi A, Nicolai N, Colecchia M, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011; 29:e650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2014; 113:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries HM, Rafael TS, Gil-Jimenez A, et al. Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial. J Clin Oncol 2023; 41:4872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apolo AB, Nadal R, Girardi DM, et al. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol 2020; 38:3672.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16866 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22818137" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29604228" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10671885" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The histological extent of the local spread of carcinoma of the penis and its therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20691883" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Penile cancer--prevention and premalignant conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421082" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28131464" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18788122" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment-seeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9763071" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Laser therapy of squamous cell dysplasia and carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441930" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Penile carcinoma. Is Nd:YAG laser therapy radical enough?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16813892" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17445665" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Long-term follow-up after laser therapy for penile carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29097087" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16925748" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Total glans resurfacing for premalignant lesions of the penis: initial outcome data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21050658" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28027867" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A Prospective Study of Total Glans Resurfacing for Localized Penile Cancer to Maximize Oncologic and Functional Outcomes in a Tertiary Referral Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17869306" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mohs micrographic surgery for penile cancer: management and long-term followup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18636264" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Radiation therapy in the management of the primary penile tumor: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28501419" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266225" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Up-to-date management of carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1399733" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Iridium-192 interstitial therapy for squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1574823" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Radiation therapy of cancer of the penis. Indications, advantages, and pitfalls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4428555" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Radiation therapy of penile cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3446239" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Carcinoma of the penis. A 12-year review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10940705" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Is conservative organ-sparing treatment of penile carcinoma justified?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9240637" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9426328" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20691884" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : New developments in the treatment of localized penile cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16225525" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : What surgical resection margins are required to achieve oncological control in men with primary penile cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15610100" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Organ-sparing surgery for invasive penile cancer: early follow-up data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15610100" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Organ-sparing surgery for invasive penile cancer: early follow-up data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18425779" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27717440" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Advances in Surgical Reconstructive Techniques in the Management of Penile, Urethral, and Scrotal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Penile squamous carcinoma. Part II: Contemporary management of the inguinal region
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20399455" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16425300" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prognostic factors in node-positive carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16425300" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prognostic factors in node-positive carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24552303" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20691887" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prognostic factors in penile cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535700" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Reproducibility of histopathologic tumor grading in penile cancer--results of a European project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18460979" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457021" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : EAU guidelines on penile cancer: 2014 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457021" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : EAU guidelines on penile cancer: 2014 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414668" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352399" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762945" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Contemporary inguinal lymph node dissection: minimizing complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3398125" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9043497" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Long-term follow-up of men undergoing modified inguinal lymphadenectomy for carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28115191" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Penile Cancer: Contemporary Lymph Node Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22901575" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Minimally invasive inguinal lymphadenectomy via endoscopic groin dissection: comprehensive assessment of immediate and long-term complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23067251" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Endoscopic inguinofemoral lymphadenectomy--extended follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23551693" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29307685" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29730734" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Robotic-assisted inguinal lymphadenectomy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34895995" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Robotic-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) and Video-Endoscopic Inguinal Lymphadenectomy (VEIL) versus Open Inguinal Lymph-Node Dissection (OILND) in carcinoma of penis: Comparison of perioperative outcomes, complications and oncological outcomes. A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25942394" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Modification of N staging systems for penile cancer: a more precise prediction of prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296384" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23876593" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Fascia lata preservation during inguinal lymphadenectomy for penile cancer: rationale and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509308" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20625118" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25294319" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7658539" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Carcinoma of the penis: improved survival by early regional lymphadenectomy based on the histological grade and depth of invasion of the primary lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9284207" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Carcinoma of the penis--appraisal of a modified tumour-staging system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3712610" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Treatment of carcinoma of the penis: the case for primary lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15711276" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8437253" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8281416" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25009098" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25009098" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26072110" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risks and benefits of adjuvant radiotherapy after inguinal lymphadenectomy and node-positive penile cancer: a systematic review by the European Association of Urology Penile Cancer Guidelines panel
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29703686" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19701032" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723934" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980189" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9164216" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11072157" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32335061" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31160252" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440124" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24924553" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Predictors of cancer-specific mortality after disease recurrence in patients with squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20691886" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7974903" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Management of advanced squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10332445" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18417462" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21871710" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22958571" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17382727" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25819619" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21632506" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24053151" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37487169" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32188704" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Phase 2 study of pembrolizumab in patients with advanced rare cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32915679" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
